Details of the Drug Reposition

General Information of This Drug (ID: DM6OZQV)

Drug Name
Daclizumab   DM6OZQV
Synonyms DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Aplastic anemia DISJRSC0 3A70 Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [2]
Kidney transplant rejection DISJ1FYS NE84 Approved [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pure red-cell aplasia DIST91OT N.A. Discontinued in Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Recent developments in drug therapy for aplastic anemia. Ann Pharmacother. 2014 Nov;48(11):1469-78.
2 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
3 Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
4 ClinicalTrials.gov (NCT00430937) Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections